FindTrial
Sign In

Risk-adapted therapeutic strategy in +1q NDMM: a prospective, multicenter study

Risk-adapted therapeutic strategy in +1q NDMM: a prospective, multicenter study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104557
Enrollment
Unknown
Registered
2025-06-19
Start date
2025-06-30
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

Observation group:None

Sponsors

The First Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Age =18, or =65 and fit according to IMWG-FI. - Newly diagnosed +1q NDMM by 2014 IMWG criteria. - Adequate organ function for systemic therapy. - Signed informed consent.

Exclusion criteria

Exclusion criteria: - Active infections requiring systemic treatment. - Unstable angina, NYHA class III–IV heart failure, or uncontrolled arrhythmias. - History of hematologic or solid tumors treated with chemo/radiotherapy within 5 years. - Current malignancies requiring therapy. - Refusal to participate.

Design outcomes

Primary

MeasureTime frame
MRD negativity rate;sustained MRD negativity rate ;—

Secondary

MeasureTime frame
PFS;OS;ORR;depth of response;—

Countries

China

Contacts

Public ContactJin Fengyan

The First Hospital of Jilin University

fengyanjin@jlu.edu.cn+86 138 4498 9638

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026